Rhodamine B and 2-acetamido-1,3,6-tri-O-acetyl-4-deoxy-4-fluoro-d-glucopyranose (F-GlcNAc) inhibit chondroitin/dermatan and keratan sulphate synthesis by different mechanisms in bovine chondrocytes

Molecular Genetics and Metabolism

Volumn 106, Issue 2, 2012, Pages 214-220

  Derrick Roberts, Ainslie L K ^a,b   Marais, Wanda ^a   Byers, Sharon ^a,b,c  

^a SA Pathology ^*  (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

F GlcNAc; Glycosaminoglycan; Mucopolysaccharidosis; Rhodamine B; Substrate deprivation therapy

Indexed keywords

2 ACETAMIDO 1,3,6 TRI O ACETYL 4 DEOXY 4 FLUORO D GLUCOPYRANOSE; CHONDROITIN; DERMATAN; GLUCOSE DERIVATIVE; GLYCOSAMINOGLYCAN; KERATAN SULFATE; PROTEOGLYCAN; RHODAMINE B; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CARTILAGE CELL; COW; GENE EXPRESSION; NONHUMAN; PRIORITY JOURNAL; SYNTHESIS;

ACETYLGLUCOSAMINE; ANIMALS; CARTILAGE; CATTLE; CHONDROCYTES; CHONDROITIN SULFATES; DERMATAN SULFATE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GLYCOSAMINOGLYCANS; KERATAN SULFATE; MUCOPOLYSACCHARIDOSES; PROTEOGLYCANS; RHODAMINES;

BOVINAE;

EID: 84860920142     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2012.04.002     Document Type: Article

References (43)

1. Neufeld E.F., Muenzer J. The Mucopolysaccharidoses. The Metabolic and Molecular Bases of Inherited Disease 2001, 3421-3452. McGraw-Hill Companies Inc., New York. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
2. Meikle P.J., Hopwood J.J., Clague A.E., Carey W.F. Prevalence of lysosomal storage disorders. JAMA 1999, 281:249-254.
3. Harmatz P., Whitley C.B., Waber L., Pais R., Steiner R., Plecko B., Kaplan P., Simon J., Butensky E., Hopwood J.J. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J. Pediatr. 2004, 144:574-580.
4. Kakkis E.D., Muenzer J., Tiller G.E., Waber L., Belmont J., Passage M., Izykowski B., Phillips J., Doroshow R., Walot I., Hoft R., Neufeld E.F. Enzyme-replacement therapy in mucopolysaccharidosis I. N. Engl. J. Med. 2001, 344:182-188.
5. Muenzer J., Lamsa J.C., Garcia A., Dacosta J., Garcia J., Treco D.A. Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report. Acta Paediatr. Suppl. 2002, 91:98-99.
6. Biomarin Pharmaceuticals last accessed 4th April, 2012. http://www.biomarinclinicaltrials.com/MPSIVA.html.
7. Wraith J.E., Clarke L.A., Beck M., Kolodny E.H., Pastores G.M., Muenzer J., Rapoport D.M., Berger K.I., Swiedler S.J., Kakkis E.D., Braakman T., Chadbourne E., Walton-Bowen K., Cox G.F. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-l-iduronidase (laronidase). J. Pediatr. 2004, 144:581-588.
8. Church H., Tylee K., Cooper A., Thornley M., Mercer J., Wraith E., Carr T., O'Meara A., Wynn R.F. Biochemical monitoring after haemopoietic stem cell transplant for Hurler syndrome (MPSIH): implications for functional outcome after transplant in metabolic disease. Bone Marrow Transplant. 2007, 39:207-210.
9. Resnick J.M., Krivit W., Snover D.C., Kersey J.H., Ramsay N.K., Blazar B.R., Whitley C.B. Pathology of the liver in mucopolysaccharidosis: light and electron microscopic assessment before and after bone marrow transplantation. Bone Marrow Transplant. 1992, 10:273-280.
10. Krivit W. Stem cell bone marrow transplantation in patients with metabolic storage diseases. Adv. Pediatr. 2002, 49:359-378.
11. Boelens J.J., Wynn R.F., O'Meara A., Veys P., Bertrand Y., Souillet G., Wraith J.E., Fischer A., Cavazzana-Calvo M., Sykora K.W., Sedlacek P., Rovelli A., Uiterwaal C.S., Wulffraat N. Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure. Bone Marrow Transplant. 2007, 40:225-233.
12. Zimran A., Elstein D. Gaucher disease and the clinical experience with substrate reduction therapy. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2003, 358:961-966.
13. Wraith J.E., Imrie J. New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat. Ther. Clin. Risk Manag. 2009, 5:877-887.
14. Malinowska M., Wilkinson F.L., Bennett W., Langford-Smith K.J., O'Leary H.A., Jakobkiewicz-Banecka J., Wynn R., Wraith J.E., Wegrzyn G., Bigger B.W. Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide IIIB mice. Mol. Genet. Metab. 2009, 98:235-242.
15. Friso A., Tomanin R., Salvalaio M., Scarpa M. Genistein reduces glycosaminoglycan levels in a mouse model of mucopolysaccharidosis type. Br. J. Pharmacol. 2010, 159:1082-1091.
16. Roberts A.L., Howarth G.S., Liaw W.C., Moretta S., Kritas S., Lymn K.A., Yazbeck R., Tran C., Fletcher J.M., Butler R.N., Byers S. Gastrointestinal pathology in a mouse model of mucopolysaccharidosis type IIIA. J. Cell. Physiol. 2009, 219:259-264.
17. Malinowska M., Wilkinson F.L., Langford-Smith K.J., Langford-Smith A., Brown J.R., Crawford B.E., Vanier M.T., Grynkiewicz G., Wynn R.F., Wraith J.E., Wegrzyn G., Bigger B.W. Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease. PLoS One 2010, 5:e14192.
18. Roberts A.L., Rees M.H., Klebe S., Fletcher J.M., Byers S. Improvement in behaviour after substrate deprivation therapy with rhodamine B in a mouse model of MPS IIIA. Mol. Genet. Metab. 2007, 92:115-121.
19. Wegrzyn G., Jakobkiewicz-Banecka J., Gabig-Ciminska M., Piotrowska E., Narajczyk M., Kloska A., Malinowska M., Dziedzic D., Golebiewska I., Moskot M., Wegrzyn A. Genistein: a natural isoflavone with a potential for treatment of genetic diseases. Biochem. Soc. Trans. 2010, 38:695-701.
20. Piotrowska E., Jakobkiewicz-Banecka J., Tylki-Szymanska A., Liberek A., Maryniak A., Malinowska M., Czartoryska B., Puk E., Kloska A., Liberek T., Baranska S., Wegrzyn A., Wegrzyn G. Genistin-rich soy isoflavone extract in substrate reduction therapy for Sanfilippo syndrome: an open-label, pilot study in 10 pediatric patients. Curr. Ther. Res. 2008, 69:166-179.
21. Roberts A.L., Fletcher J.M., Moore L., Byers S. Trans-generational exposure to low levels of rhodamine B does not adversely affect litter size or liver function in murine mucopolysaccharidosis type IIIA. Mol. Genet. Metab. 2010, 101:208-213.
22. Piotrowska E., Jakobkiewicz-Banecka J., Baranska S., Tylki-Szymanska A., Czartoryska B., Wegrzyn A., Wegrzyn G. Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses. Eur. J. Hum. Genet. 2006, 14:846-852.
23. Roberts A.L., Thomas B.J., Wilkinson A.S., Fletcher J.M., Byers S. Inhibition of glycosaminoglycan synthesis using rhodamine B in a mouse model of mucopolysaccharidosis type IIIA. Pediatr. Res. 2006, 60:309-314.
24. Arfi A., Richard M., Gandolphe C., Scherman D. Storage correction in cells of patients suffering from mucopolysaccharidoses types IIIA and VII after treatment with genistein and other isoflavones. J. Inherit. Metab. Dis. 2010, 33:61-67.
25. Kloska A., Jakobkiewicz-Banecka J., Narajczyk M., Banecka-Majkutewicz Z., Wegrzyn G. Effects of flavonoids on glycosaminoglycan synthesis: implications for substrate reduction therapy in Sanfilippo disease and other mucopolysaccharidoses. Metab. Brain Dis. 2011, 26:1-8.
26. Dziedzic D., Wegrzyn G., Jakobkiewicz-Banecka J. Impairment of glycosaminoglycan synthesis in mucopolysaccharidosis type IIIA cells by using siRNA: a potential therapeutic approach for Sanfilippo disease. Eur. J. Hum. Genet. 2010, 18:200-205.
27. Kaidonis X., Liaw W.C., Roberts A.D., Ly M., Anson D., Byers S. Gene silencing of EXTL2 and EXTL3 as a substrate deprivation therapy for heparan sulphate storing mucopolysaccharidoses. Eur. J. Hum. Genet. 2010, 18:194-199.
28. van Wijk X.M., Oosterhof A., van den Broek S.A., Griffioen A.W., ten Dam G.B., Rutjes F.P., van Delft F.L., van Kuppevelt T.H. A 4-deoxy analogue of N-acetyl-d-glucosamine inhibits heparan sulphate expression and growth factor binding in vitro. Exp. Cell Res. 2010, 316:2504-2512.
29. Berkin A., Szarek W.A., Kisilevsky R. Synthesis of 4-deoxy-4-fluoro analogues of 2-acetamido-2-deoxy-d-glucose and 2-acetamido-2-deoxy-d-galactose and their effects on cellular glycosaminoglycan biosynthesis. Carbohydr. Res. 2000, 326:250-263.
30. Dimitroff C.J., Bernacki R.J., Sackstein R. Glycosylation-dependent inhibition of cutaneous lymphocyte-associated antigen expression: implications in modulating lymphocyte migration to skin. Blood 2003, 101:602-610.
31. Dimitroff C.J., Kupper T.S., Sackstein R. Prevention of leukocyte migration to inflamed skin with a novel fluorosugar modifier of cutaneous lymphocyte-associated antigen. J. Clin. Invest. 2003, 112:1008-1018.
32. Woynarowska B., Dimitroff C.J., Sharma M., Matta K.L., Bernacki R.J. Inhibition of human HT-29 colon carcinoma cell adhesion by a 4-fluoro-glucosamine analogue. Glycoconj. J. 1996, 13:663-674.
33. Nigro J., Wang A., Mukhopadhyay D., Lauer M., Midura R.J., Sackstein R., Hascall V.C. Regulation of heparan sulfate and chondroitin sulfate glycosaminoglycan biosynthesis by 4-fluoro-glucosamine in murine airway smooth muscle cells. J. Biol. Chem. 2009, 284:16832-16839.
34. Roughley P.J. The structure and function of cartilage proteoglycans. Eur. Cell. Mater. 2006, 12:92-101.
35. Byers S., Rothe M., Lalic J., Koldej R., Anson D.S. Lentiviral-mediated correction of MPS VI cells and gene transfer to joint tissues. Mol. Genet. Metab. 2009, 97:102-108.
36. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
37. Valayannopoulos V., Wijburg F.A. Therapy for the mucopolysaccharidoses. Rheumatology (Oxford) 2011, 50(Suppl. 5):v49-v59.
38. Byers S., Crawley A.C., Brumfield L.K., Nuttall J.D., Hopwood J.J. Enzyme replacement therapy in a feline model of MPS VI: modification of enzyme structure and dose frequency. Pediatr. Res. 2000, 47:743-749.
39. Maroudas A. Distribution and diffusion of solutes in articular cartilage. Biophys. J. 1970, 10:365-379.
40. Chatzinikolaou G., Nikitovic D., Stathopoulos E.N., Velegrakis G.A., Karamanos N.K., Tzanakakis G.N. Protein tyrosine kinase and estrogen receptor-dependent pathways regulate the synthesis and distribution of glycosaminoglycans/proteoglycans produced by two human colon cancer cell lines. Anticancer. Res. 2007, 27:4101-4106.
41. Jakobkiewicz-Banecka J., Piotrowska E., Narajczyk M., Baranska S., Wegrzyn G. Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway. J. Biomed. Sci. 2009, 16:26.
42. Schonherr E., Kinsella M.G., Wight T.N. Genistein selectively inhibits platelet-derived growth factor-stimulated versican biosynthesis in monkey arterial smooth muscle cells. Arch. Biochem. Biophys. 1997, 339:353-361.
43. Kaji T., Kawashima T., Sakamoto M. Rhodamine B inhibition of glycosaminoglycan production by cultured human lip fibroblasts. Toxicol. Appl. Pharmacol. 1991, 111:82-89.